The role of arterial hypertension in developement of chronic renal failure;Uloga arterijske hipertenzije u nastanku kroničnog zatajenja bubrega

Acta Medica Croatica

Volumn 65, Issue SUPP 3, 2011, Pages 78-84

  Kes, Petar ^a   Bašić Jukić, Nikolina ^a   Ljutić, Dragan ^b   Brunetta Gavranić, Bruna ^a  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Antihypertensive medication; Arterial hypertension; Chronic kidney disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INJURY; NEPHROSCLEROSIS; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW;

HUMANS; HYPERTENSION; HYPERTENSION, RENOVASCULAR; KIDNEY FAILURE, CHRONIC;

EID: 84862860557     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. http://www.hdndt.org/registar-forward.htm
2. Kes P. Da li je moguće spriječiti, usporiti i liječiti kronične progresivne bolest bubrega. Acta Med Croatica 2008; 62(Suppl 1): 1-2.
3. Hunsicker LG , Adler S, Caggiula A, i sur. Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int 1997; 51:1908-19.
4. Ljutić D, Kes P. The role of arterial hypertension in the progression of non-diabeticglomerular diseases. Nephrol D ial Transplant 2003; 18(Suppl 5): 28-30.
5. Brewster, UC, Perazella, MA. The renin-angiotensin-aldosterone system and thekidney: effects on kidney disease. Am J Med 2004; 116:263-71.
6. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II .Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int 1992; 42:148-60.
7. Shankland SJ, Ly H, Thai K, Scholey JW. Increased glomerular capillary pressurealters glomerular cytokine expression. Circ Res 1994; 75:844-53.
8. Rosenberg ME, Hostetter TH. Comparative effects of antihypertensives on proteinuria: A ngiotensin-converting enzyme inhibitor versus alpha 1-antagonist. Am J Kidney Dis 1991; 18:472-82.
9. Raij L. End-organ susceptibility as a determinant of renal disease in hypertension. Kidney Int 2003; 64: 1923-32.
10. Bedogna V, Valvo E, Casagrande P, i sur. Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int 1990; 38: 101-7.
11. Bakris GL , Weir MR, Secic M, i sur. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65:1991-2002.
12. Remuzzi A, Perticucci E, Ruggenenti P, i sur. Angiotensin converting enzyme inhibition improves glomerular size selectivity in IgA nephropathy. Kidney Int 1991; 39:1267-73.
13. Hoffmann S, Podlich, D, Hahnel B, i sur. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004;15:1475-87.
14. Yoshida H, Mitarai T, Kawamura T, i sur. Role of the deletion polymorphism of angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96:2162-9.
15. Ots M, Mackenzie HS, Troy JL , i sur. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am S oc Nephrol 1998; 9:224-30.
16. Brunskill NJ . Albumin signals the coming of age of proteinuric nephropathy. J Soc Nephrol 2004; 15: 504-5.
17. Lee HS, Lee JS , Koh HI, and Ko KW. Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 1991; 36: 67-75
18. Schaeffner ES , Kurth T, Curhan GC, Glynn RJ , Rexrode KM, Baigent C, Buring JE , and Gaziano JM. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-91.
19. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE ): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1004-10.
20. Fried LF, Orchard TJ , Kasiske BL . Effect of lipid reduction on the progression of renal disease: a metaanalysis. Kidney I nt 2001; 59: 260-9.
21. Bakris GL et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-61.
22. Vasiljević Z, Bošković A, Ostojić M, Prostran M, Kocev N. Long-term effect of captopril on plasma lipids in acute myocardial infarction: possible mechanism of, antiatherosclerotical effect of ACE inhibition. Med Biol 1999; 6: 69-72.
23. Rader DJ, Dugi KA. The endothelium and lipoproteins: insights from recent cell biology and animal studies. Semin T hromb Hemost 2000; 26: 521-8.
24. Bakris GL, Smith AC, Richardson DJ, Hung E, Preston R, Goldberg R, Epstein M. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. J Hum Hypert 2002; 16, 185-19.
25. Kes P, Reiner Ž, Brunetta B. Poremećaji lipoproteina u kroničnom zatajenju bubrega, nefrotskom sindromu i dijalizi. Liječ Vjesn 2002; 124: 372-7.
26. Klahr S, Levey AS, Beck GJ, i sur. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330:877-84.
27. Maschio G, Alberti D, Janin G, i sur. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
28. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-63.
29. Ruggenenti P, Perna A, Gherardi G, i sur. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998;352:1252-6.
30. Ruggenenti P, Perna A, Gherardi G, i sur. Renoprotective properties of ACE- Inhibitio in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354:359-64.
31. Ruggenenti P, Perna A, Remuzzi G. ACE enhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial results. J Am Soc Nephrol 2001; 12:2832-7.
32. Nakao, N, Yoshimura, A, Morita, H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE ): A randomized controlled trial. Lancet 2003; 361:117-24.
33. Jelaković B, Kuzmanić D, Miličić D, i sur. Smjernice za dijagnosticiranje i liječenje arterijske hipertenzije. Praktične preporuke hrvatske radne skupine i osvrt na smjenice ESH/ESC 2007. Liječ Vjesn 2008; 130:115-132.
34. Ljutić D, Kes P. The role of arterial hypertension in the progression of non-diabetic glomerular diseases. Nephrol Dial Transplant 2003; 18 [Suppl 5]: v28-v30.